171 related articles for article (PubMed ID: 24994039)
1. Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis.
Yao A; Wang Y; Peng X; Ye R; Wang Q; Qi Y; Zhou F
J Cancer Res Clin Oncol; 2014 Dec; 140(12):2107-17. PubMed ID: 24994039
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis.
Wei KK; Jiang L; Wei YY; Wang YF; Qian XK; Dai Q; Guan QL
Tumour Biol; 2014 Sep; 35(9):8721-31. PubMed ID: 24870596
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis.
Lv Y; Xu M; Sun Y; Liu Y; Zhao L; Liu X; Li Z; Shi G; Jia J; Bi L; Ma N; Zhang X; Qi C
Medicine (Baltimore); 2021 Aug; 100(33):e26850. PubMed ID: 34414935
[TBL] [Abstract][Full Text] [Related]
4. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.
Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
Mol Biol Rep; 2012 Jun; 39(6):6933-42. PubMed ID: 22302397
[TBL] [Abstract][Full Text] [Related]
6. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.
Yang Y; Luo X; Yang N; Feng R; Xian L
PLoS One; 2014; 9(11):e111651. PubMed ID: 25375151
[TBL] [Abstract][Full Text] [Related]
8. ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis.
Li S; Wu J; Chen Y; Tang W; Peng Q; Deng Y; Xie L; Wang J; Huang S; Li R; Qin X; Zhao J
Anticancer Drugs; 2014 Jan; 25(1):106-14. PubMed ID: 24025563
[TBL] [Abstract][Full Text] [Related]
9. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations.
Hubner RA; Riley RD; Billingham LJ; Popat S
PLoS One; 2011; 6(10):e25164. PubMed ID: 22022380
[TBL] [Abstract][Full Text] [Related]
10. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
[TBL] [Abstract][Full Text] [Related]
11. [Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].
Liu YP; Ling Y; Zhang YP; Liu BR
Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):256-9. PubMed ID: 21418871
[TBL] [Abstract][Full Text] [Related]
12. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Yang Y; Xian L
Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
[TBL] [Abstract][Full Text] [Related]
13. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
[TBL] [Abstract][Full Text] [Related]
14. [Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology].
Huang J; Hu H; Xie Y; Tang Y; Liu W; Zhong M
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):582-9. PubMed ID: 23828702
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis.
Song P; Yin Q; Lu M; Fu BO; Wang B; Zhao Q
Exp Ther Med; 2015 Apr; 9(4):1393-1400. PubMed ID: 25780441
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Roth JA; Carlson JJ
Clin Lung Cancer; 2011 Nov; 12(6):393-401. PubMed ID: 21723790
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.
Li FY; Ren XB; Xie XY; Zhang J
Asian Pac J Cancer Prev; 2013; 14(12):7203-6. PubMed ID: 24460276
[TBL] [Abstract][Full Text] [Related]
19. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
Rubatt JM; Darcy KM; Tian C; Muggia F; Dhir R; Armstrong DK; Bookman MA; Niedernhofer LJ; Deloia J; Birrer M; Krivak TC
Gynecol Oncol; 2012 May; 125(2):421-6. PubMed ID: 22261301
[TBL] [Abstract][Full Text] [Related]
20. Predictive Value of Excision Repair Cross-Complementation Group 1 in the Response to Platinum-Based Chemotherapy in Esophageal Cancer: A Meta-Analysis.
Zhuo ZG; Zhu YK; Deng HY; Li G; Luo J; Alai GH; Lin YD
Oncol Res Treat; 2020; 43(4):160-169. PubMed ID: 31958797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
